Late-LOE Exemplars

ALX Engine

Licensing Functionally Superior Successors — Before LOE Closes and the Competition Locks You Out

Licensing InquiriesManufacturing Inquiries
ALX Drug Exemplars

Late-LOE Pipeline Intelligence

Sixteen marketed small-molecule drugs approaching loss of exclusivity between 2032 and 2040. Each exemplar profiles the drug’s known imperfections and how ALX — A Precision Prodrug Engine could address these gaps.

Licensing InquiriesManufacturing Inquiries

All 16 Late-LOE Exemplar Drugs

EVRYSDI

risdiplam
SMN2 Splicing Modifier
·
Spinal Muscular Atrophy (SMA)
~$1.0B
2035–2036

ALECENSA

alectinib
2nd-Gen ALK Inhibitor
·
ALK+ NSCLC
~$1.7B
2034–2036

TAFINLAR

dabrafenib
BRAF V600 Kinase Inhibitor
·
BRAF+ Melanoma
~$700M
2034–2036

SPRYCEL

dasatinib
2nd-Gen BCR-ABL/SRC Inhibitor
·
CML
~$2.0B
2034–2035

POMALYST

pomalidomide
3rd-Generation IMiD / CELMoD
·
Multiple Myeloma
~$3.5B
2034–2035

REVLIMID

lenalidomide
IMiD / Thalidomide Analogue (CELMoD Backbone)
·
Multiple Myeloma
~$6.0B
2036

VENCLEXTA

venetoclax
BCL-2 Inhibitor
·
CLL / AML
~$2.5B
2032–2033

MAVYRET

glecaprevir/pibrentasvir
Pangenotypic NS3/4A + NS5A Inhibitor (DAA Combination)
·
HCV
~$3.0B
2032–2034

VERQUVO

vericiguat
Soluble Guanylate Cyclase (sGC) Stimulator
·
Heart Failure
~$300M
2032

FARXIGA

dapagliflozin
SGLT2 Inhibitor
·
T2D / HF / CKD
~$6.0B
2033–2034

BRILINTA

ticagrelor
Reversible P2Y12 ADP Receptor Inhibitor
·
ACS
~$1.7B
2033–2034

PRANDIN

repaglinide
Meglitinide / Short-Acting Insulin Secretagogue
·
T2D
~$200M
2032–2033

AVODART

dutasteride
Dual 5-Alpha Reductase Inhibitor (Type 1 and Type 2)
·
BPH
~$500M
2032–2033

AUBAGIO

teriflunomide
DHODH Inhibitor / Oral Immunomodulator
·
MS
~$2.0B
2034

MULTAQ

dronedarone
Non-Iodinated Multi-Channel Antiarrhythmic (Benzofuran)
·
AFib
~$600M
2033–2034

TEPMETKO

tepotinib
Highly Selective MET Kinase Inhibitor
·
MET+ NSCLC
~$300M
2038–2040

Successor Drug Strategy

ALX enables partners to create structurally distinct successor drugs before LOE closes. Each ALX variant is a new chemical entity (NCE) with improved PK, exposure, or tolerability, enabling franchise protection and accelerated 505(b)(2) development.